New drug cocktail takes on rare skin cancer
NCT ID NCT07529405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tests a new drug called VG712 against an existing drug, mogamulizumab, in about 386 people with advanced mycosis fungoides, a rare type of skin lymphoma. VG712 is designed to kill cancerous immune cells by blocking protein production. The study aims to see if VG712 can delay cancer progression better than the current treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VG712 (a fusion protein that targets and kills certain immune cells) and mogamulizumab (a targeted antibody therapy)
What this could lead to
If successful, this could offer a new treatment option for people with advanced mycosis fungoides who have not responded to other therapies.
What could go wrong
This is a Phase II trial, so it is still early. The treatment may not work better than the comparison drug, and side effects could include infusion reactions or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact